Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis

Abstract

ObjectiveTo study the incidence and distribution of adverse events in immune checkpoint inhibitors (ICI) for digestive system cancers and to provide a reference for the safe, rational, and effective use of immune detection site inhibitors.MethodsWe searched for articles published in English between January 1, 2010, and May 18, 2022. All clinical trials of ICI-based therapies for digestive system cancers were investigated, including only randomized controlled trials that reported data on the overall incidence of treatment-related adverse events (trAEs) or immune-related adverse reactions (irAEs) or tables.ResultsWe searched 2048 records, of which 21 studies (7108 patients) were eligible for inclusion. The incidence of ICI trAEs of any grade was 82.7% (95% CI 73.9-90.0), and the incidence of grade 3 or higher trAEs was 27.5% (95% CI 21.3-34.1). The pooled rate of ICI irAEs of any grade was 26.3% (95% CI 11.8-44.0), and the incidence of grade 3 or higher irAEs was 9.4% (95% CI 1.1-24.6). In multivariate analysis, the incidence, characteristics, and distribution of AEs varied by cancer type, combination therapy modality (single/two-drug), and different agent types.ConclusionOur meta-analysis summarizes AEs associated with ICI in digestive system cancers. The incidence, characteristics, and distribution of AEs vary by cancer type, combination therapy modality, and different agent types. These findings can be considered for the early identification of AEs and provide effective interventions to reduce the severity of these patients. It can provide a clinical reference and may contribute to clinical practice.

Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review

“…Most immunotherapy-related adverse effects were manageable, some resolving after treatment discontinuation, and others responding well to corticosteroid therapy. Overall, neoadjuvant immunotherapy in HCC demonstrated safety akin to previous studies in gastrointestinal tumors ( 39 ).Furthermore, the highest occurrence rate of grade 3-4 adverse events reported in this study was 43% (reported by Kaseb, A.O. et al.…”

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman

“…Previous studies have hypothesized that the reason for this low incidence may be because of significant heterogeneity and unobserved confounders such as the disease site, concomitant therapies, and other concomitant medications [14]. Additionally, others considered irAEs to be influenced by many factors including, but not limited to, age, BMI, smoking, comorbidities, and performance status (PS) [15].…”

Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials

“…Despite the favorable clinical benefits of checkpoint inhibition, it has side effects known as immune-related adverse events (irAEs) (13,14). IrAEs include skin diseases, diarrhea, hepatotoxicity, and cardiotoxicity (15)(16)(17)(18)(19). Checkpoint inhibition may also cause fulminant or fatal toxic reactions (20).…”